VIVUS Settlement Could Clue In Orexigen Investors

Published: Jul 21, 2017

The prescription anti-obesity sector has had its challenges over the years. After more than a decade with no new treatments for obesity, three companies developed, received approval for, and launched anti-obesity drugs a few years ago. Investors thought that a new anti-obesity treatment was a "no-brainer" and piled into Vivus (VVUS), Arena Pharmaceuticals (ARNA), and Orexigen (OREX). Ultimately, each company struggled in a big way to find enough patients to drive sales to respectable levels.

Back to news